Steven Cohen Relmada Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.45 - $4.22 $612,500 - $1.06 Million	250,000 New	250,000 $1.03 Million
Q2 2023 Aug 14, 2023	BUY	$2.22 - $3.54 $10,440 - $16,648	4,703 New	4,703 $11,000
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $7.97 Million - $16.1 Million	-435,384 Reduced 34.21%	837,190 $31 Million
Q2 2022 Aug 15, 2022	SELL	$16.5 - $30.34 $657,129 - $1.21 Million	-39,826 Reduced 3.03%	1,272,574 $24.2 Million
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $6.12 Million - $9.88 Million	366,087 Added 38.69%	1,312,400 $35.4 Million
Q4 2021 Feb 14, 2022	BUY	$16.93 - $26.82 $12.3 Million - $19.5 Million	726,313 Added 330.14%	946,313 $21.3 Million
Q3 2021 Nov 15, 2021	BUY	$21.86 - $34.77 $557,211 - $886,287	25,490 Added 13.1%	220,000 $5.77 Million
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $650,395 - $861,691	22,010 Added 12.76%	194,510 $6.23 Million
Q1 2021 May 17, 2021	SELL	$31.52 - $39.28 $3.55 Million - $4.42 Million	-112,500 Reduced 39.47%	172,500 $6.07 Million
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $2.56 Million - $3.41 Million	85,709 Added 43.01%	285,000 $9.14 Million
Q3 2020 Nov 16, 2020	BUY	$34.42 - $43.78 $1.2 Million - $1.52 Million	34,732 Added 21.11%	199,291 $7.5 Million
Q2 2020 Aug 14, 2020	BUY	$31.59 - $49.98 $5.2 Million - $8.22 Million	164,559 New	164,559 $7.36 Million
Q1 2020 May 15, 2020	SELL	$23.78 - $50.12 $3.26 Million - $6.86 Million	-136,900 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$10.1 - $47.18 $1.38 Million - $6.46 Million	136,900 New	136,900 $5.34 Million

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $8.58M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.